These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 1664989

  • 1. Control of viral disease: the development of Epstein-Barr virus vaccines.
    Morgan AJ.
    Springer Semin Immunopathol; 1991; 13(2):249-62. PubMed ID: 1664989
    [No Abstract] [Full Text] [Related]

  • 2. Candidate vaccines for Epstein-Barr virus.
    Moss DJ, Suhrbier A, Elliott SL.
    BMJ; 1998 Aug 15; 317(7156):423-4. PubMed ID: 9703518
    [No Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus vaccines.
    Morgan AJ.
    Vaccine; 1992 Aug 15; 10(9):563-71. PubMed ID: 1323899
    [Abstract] [Full Text] [Related]

  • 4. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum.
    Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ.
    Vaccine; 1994 Oct 15; 12(13):1180-4. PubMed ID: 7839721
    [Abstract] [Full Text] [Related]

  • 5. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.
    Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ.
    J Gen Virol; 1993 Mar 15; 74 ( Pt 3)():501-7. PubMed ID: 8383183
    [Abstract] [Full Text] [Related]

  • 6. [New perspectives in the search for a vaccine against the Epstein-Barr virus].
    Cour Boveda MI, Yagüe García V.
    An Med Interna; 1991 Nov 15; 8(11):527-8. PubMed ID: 1665087
    [No Abstract] [Full Text] [Related]

  • 7. Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge.
    Cox C, Naylor BA, Mackett M, Arrand JR, Griffin BE, Wedderburn N.
    J Med Virol; 1998 Aug 15; 55(4):255-61. PubMed ID: 9661832
    [Abstract] [Full Text] [Related]

  • 8. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.
    Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA.
    J Med Virol; 1988 Jun 15; 25(2):189-95. PubMed ID: 2839612
    [Abstract] [Full Text] [Related]

  • 9. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours.
    Epstein MA.
    Proc R Soc Lond B Biol Sci; 1984 Mar 22; 221(1222):1-20. PubMed ID: 6144103
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus. Dream or reality of a vaccine?
    Beale AJ.
    Nature; 1984 Mar 22; 318(6043):230. PubMed ID: 2999603
    [No Abstract] [Full Text] [Related]

  • 11. Epstein-barr-virus nuclear antigen.
    Vonka V, Hirsch I.
    Prog Med Virol; 1982 Mar 22; 28():145-79. PubMed ID: 6283600
    [No Abstract] [Full Text] [Related]

  • 12. Vaccination against Epstein-Barr virus: current progress and future strategies.
    Epstein MA.
    Lancet; 1986 Jun 21; 1(8495):1425-7. PubMed ID: 2872525
    [Abstract] [Full Text] [Related]

  • 13. The Epstein-Barr virus genome and phenotypic expression during lytic cycle.
    Pearson GR.
    AIDS Res; 1986 Dec 21; 2 Suppl 1():S49-56. PubMed ID: 3030347
    [Abstract] [Full Text] [Related]

  • 14. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ.
    J Gen Virol; 1992 Feb 21; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [Abstract] [Full Text] [Related]

  • 15. Distribution of antibody to Epstein-Barr virus among patients with haematologic malignancies.
    Advani SH, Connelly RR, Ablashi DV.
    Indian J Med Res; 1988 Mar 21; 87():240-5. PubMed ID: 2840391
    [No Abstract] [Full Text] [Related]

  • 16. Vaccine control of malignancies induced by lymphotropic herpesviruses.
    Epstein MA, North JR, Morgan AJ.
    Prog Clin Biol Res; 1983 Mar 21; 132B():61-70. PubMed ID: 6314351
    [No Abstract] [Full Text] [Related]

  • 17. Issues related to development of Epstein-Barr virus vaccines.
    Spring SB, Hascall G, Gruber J.
    J Natl Cancer Inst; 1996 Oct 16; 88(20):1436-41. PubMed ID: 8841018
    [No Abstract] [Full Text] [Related]

  • 18. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.
    Ooka T, de Turenne-Tessier M, Stolzenberg MC.
    Springer Semin Immunopathol; 1991 Oct 16; 13(2):233-47. PubMed ID: 1664988
    [No Abstract] [Full Text] [Related]

  • 19. Immunological control of human lymphoma: discussion.
    Klein E, Klein G, Levin PH.
    Cancer Res; 1976 Feb 16; 36(2 pt 2):724-7. PubMed ID: 56225
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies.
    Robertson KD, Barletta J, Samid D, Ambinder RF.
    Curr Top Microbiol Immunol; 1995 Feb 16; 194():145-54. PubMed ID: 7534666
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.